Nav: Home

Heating up tumors could make CAR T therapy more effective, study finds

March 27, 2019

FINDINGS

A preclinical study led by scientists at the UCLA Jonsson Comprehensive Cancer suggests that heating solid tumors during CAR T-cell therapy can enhance the treatment's success.

The researchers found that when a heating technique called photothermal ablation was combined with the infusion of CAR T cells, it suppressed melanoma tumor growth for up to 20 days in mice. Among the mice that were treated with the combination, 33 percent were still tumor free after the 20-day mark.

BACKGROUND

T cells that have been genetically engineered with chimeric antigen receptor, or CAR, have successfully been used to treat many patients with lymphoma and leukemia. But CAR T cell therapy has been less successful for treating solid tumors because the tumors have a protective microenvironment, which makes it harder for the CAR T cells to break into the tumor and keep the T cells activated.

The UCLA scientists decided to test whether combining CAR T therapy with photothermal therapy could overcome that obstacle. Photothermal therapy is a minimally invasive technique that uses heat from laser energy to kill cancer cells; it is already being used to treat a variety of cancers and other medical conditions. The researchers tested a mild hyperthermia about 40 degrees Celsius (about 104 degrees Fahrenheit) to see if it could help enhance the CAR T cells to better attack the tumor.

METHOD

The UCLA-led team tested the technique in mice that were injected with human melanoma tumors. A photothermal agent was injected into the tumors and then irradiated with the laser to heat them. Then, CAR T cells were injected intravenously. Raising the temperature of the laser to about 40 degrees Celsius helped expand blood vessels associated with the tumor, enhancing T cell growth.

IMPACT

By enhancing the power of CAR T cell therapy, the technique could eventually improve the prognosis for people with hard-to-treat solid tumors. The researchers will continue testing the strategy in animals to optimize the heating duration and temperature before determining whether it can be tested on humans.

AUTHORS

Zhen Gu, a professor of bioengineering at the UCLA Samueli School of Engineering, member of the Jonsson Cancer Center and member of the California NanoSystems Institute at UCLA, is the study's co-senior author. The paper's other senior author is Dr. Gianpietro Dotti of the University of North Carolina, Chapel Hill. The first author is Qian Chen, a postdoctoral researcher in Gu's laboratory.
-end-
JOURNAL

The research is published in the journal Advanced Materials.

FUNDING

The study was supported by grants from the Alfred P. Sloan Foundation and a National Institutes of Health Clinical and Translational Science Award.

The UCLA Jonsson Comprehensive Cancer Center has approximately 500 researchers and clinicians engaged in cancer research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the UCLA Jonsson Comprehensive Cancer Center is dedicated to promoting research and translating basic science into leading-edge clinical studies.

University of California - Los Angeles Health Sciences

Related Tumors Articles:

Mammograms: Are we overdiagnosing small tumors?
An analysis of breast cancer data revealed that many small breast cancers have an excellent prognosis because they are inherently slow growing, according to Yale Cancer Center experts.
The complete epigenomes of the most frequent tumors, unveiled
An IDIBELL research team manages to characterize the complete epigenomes of the most frequent tumors, including those of colon, lung and breast cancer.
Attacking metastatic tumors in the brain
Rakesh Jain, Ph.D., Director of the Edwin L. Steele Laboratory for Tumor Biology at the Massachusetts General Hospital and supported by the National Foundation for Cancer Research, has discovered a novel mechanism behind the resistance to HER2- or PI3K-targeted therapies, and a treatment strategy that may overcome treatment resistance.
New technology can detect tiny ovarian tumors
MIT engineers have developed a highly sensitive way to reveal ovarian tumors: In tests in mice, they were able to detect tumors smaller than 2 millimeters in diameter.
Beyond genomics: Using proteomics to target tumors
Dr. Amanda Paulovich, whose lab has a leading role in the Beau Biden Cancer Moonshot, will speak April 5 at the AACR annual meeting about her lab's pioneering methods to measure proteins that serve as tumor markers.
How best to treat infections and tumors
A new research analysis provides physicians and patients with new information to help them make difficult decisions about how to treat tumors and infections.
New pharmacon allows testicular tumors to shrink
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
Why tumors evade immunotherapy
Immunotherapy is a new and highly promising form of treatment for cancer, but in many patients, tumors recur.
Novel antibody against brain tumors
Scientists of Helmholtz Zentrum M√ľnchen and the Munich University Hospital (LMU) are developing a novel antibody to treat brain tumors.
A better way to diagnose and manage neuroendocrine tumors
A recent study reported in the May issue of the Journal of Nuclear Medicine demonstrates that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in the United States for detecting neuroendocrine tumors, and could significantly impact treatment management.

Related Tumors Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...